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Skin changes caused by ionizing radiation have been
scientifically documented since 1902. Ionizing radia-
tion is a widely accepted form of treatment for various
types of cancer. Despite the technological advances,
radiation skin injury remains a significant problem.
This injury, often referred to as radiation dermatitis,
occurs in about 95% of patients receiving radiation
therapy for cancer, and ranges in severity from mild
erythema to moist desquamation and ulceration.
Ionizing radiation is not only a concern for cancer
patients, but also a public health concern because
of the potential for and reality of a nuclear and/or
radiological event. Recently, the United States has
increased efforts to develop medical counter-
measures to protect against radiation toxicities from
acts of bioterrorism, as well as cancer treatment.
Management of radiation dermatitis would improve
the therapeutic benefit of radiation therapy for cancer
and potentially the mortality expected in any ‘‘dirty
bomb’’ attack. Currently, there is no effective treat-
ment to prevent or mitigate radiation skin injury.
This review summarizes ‘‘the good, the bad, and the
ugly’’ of current and evolving knowledge regarding
mechanisms of and treatments for radiation skin
injury.
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CURRENT UNDERSTANDING: PERCEPTION OF
RADIATION SKIN INJURY
Radiation exposure
Radiation injury involves morphological and functional
changes that occur in noncancerous or ‘‘normal’’ tissue as
a direct result of ionizing radiation (Mendelsohn et al., 2002).
b-radiation can penetrate several centimeters into the skin,
whereas g-radiation can penetrate through the skin and into
the human body (Wolbarst et al., 2010). The degree of
radiation injury is related to the total radiation dose,
proportion of body irradiated, volume of tissues irradiated,
and the time interval of the radiation dose received (Hall and
Giaccia, 2006; Cox and Ang, 2010). The most radiosensitive
cells in the body are those that are highly proliferative and
sufficiently oxygenated. The most radiosensitive organ
systems are bone marrow, reproductive and gastrointestinal
systems, skin, muscle, and the brain (Hall and Giaccia, 2006;
Cox and Ang, 2010). Organ systems are more tolerant to low-
dose radiation exposure over a long period of time, as used in
fractionated radiotherapy, compared with high local radia-
tion exposure or total body irradiation (Hall and Giaccia,
2006; Cox and Ang, 2010). For example, radiotherapy for
breast cancer involves fractionated radiation doses of B2Gy
for 6 weeks for a total radiation dose ofX50Gy. A total body
irradiation dose of 100Gy would result in 100% chance of
death within hours of radiation exposure (Hall and Giaccia,
2006; Cox and Ang, 2010). The total body irradiation dose at
which death will occur in 50% of individuals (LD50) is 3–4Gy
(Hall and Giaccia, 2006; Cox and Ang, 2010). Although the
kinetics of the clinical signs of radiation exposure may differ
between cancer radiotherapy and a ‘‘dirty bomb’’ attack, the
symptoms and syndromes in exposed organ systems are
similar (Williams and McBride, 2011).
Radiation skin injury
The main function of skin is to establish an effective physical
and immunological barrier against the surrounding environ-
ment. The epidermis, the outermost layer of the skin,
primarily composed of stratifying layers of keratinocytes,
functions as the primary barrier and biosensor to the external
environment. The dermis is immediately underneath the
epidermis, providing structural strength to the skin. It is
primarily composed of connective tissue produced by dermal
fibroblasts. Skin is susceptible to radiation damage because it
is a continuously renewing organ containing rapidly prolif-
erating and maturing cells. The basal keratinocytes, hair
follicle stem cells, and melanocytes are highly radiosensitive
(Mendelsohn et al., 2002; McQuestion, 2011). Radiation
skin injury involves immediate damage to basal keratinocytes
and hair follicle stem cells, followed by a burst of free
radicals, irreversible double-stranded breaks in nuclear and
mtDNA, and inflammation (Mendelsohn et al., 2002; Eide
and Weinstock, 2005; Lopez et al., 2005; Hymes et al., 2006;
McQuestion, 2011). During radiation therapy, the first
fractionated dose of radiation destroys a percentage of basal
keratinocytes, resulting in a disruption in the self-renewing
property of the epidermis (McQuestion, 2011). These
repeated exposures do not allow time for cells to repair
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tissue or DNA damage. Although the remaining keratinocytes
are stimulated to proliferate, these cells are continually
destroyed with each fractionated radiation treatment. There-
fore, it is not surprising that cancer patients undergoing
radiation therapy experience skin reactions, as well as other
symptoms (Hickok et al., 2005). Radiation skin injury occurs
in about 95% of patients receiving radiation treatment for
cancer (Salvo et al., 2010; McQuestion, 2011). Radiation skin
injury has also been reported in over 70 cases of fluorosco-
pically guided procedures because of the lack of awareness
of radiation exposure to skin during the procedure (Brown
and Rzucidlo, 2011). Reported entrance doses from fluoro-
scopically guided procedures have ranged from 2 to 58Gy
(Brown and Rzucidlo, 2011). Radiation skin toxicities can
negatively affect the quality of a patient’s life because of pain
and premature interruption of radiation treatment, which in
turn may impair control of disease (Duncan et al., 1996;
Robertson et al., 1998; Salvo et al., 2010; McQuestion,
2011). Despite substantial improvements in radiation tech-
nology, such as intensity-modulated radiation therapy,
radiation skin injury is still a concerning problem (Pignol
et al., 2008; Salvo et al., 2010; McQuestion, 2011).
Radiation skin injury can be categorized as acute or late
(i.e., chronic) injuries (Table 1). Acute injury occurs within
hours to weeks after radiation exposure, whereas late injury
presents months to years after radiation exposure (Mendel-
sohn et al., 2002; Salvo et al., 2010; Wolbarst et al., 2010;
McQuestion, 2011). Individuals who experience severe acute
injury are not more susceptible to severe late injury (Meyer
et al., 2011). Acute radiation skin injury primarily involves
cellular alterations and inflammation in the epidermis and the
dermis. Acute effects begin with erythema, edema, pigment
changes, and depilation. Although histological analyses
of irradiated skin show hyperproliferation of the epidermis
and thickening of the stratum corneum, transepidermal water
loss, a measure for skin barrier integrity, is significantly
increased (Schmuth et al., 2001; Jensen et al., 2011). Severe
radiation injury results in complete loss of the epidermis and
in persistent fibrinous exudates and edema. Re-epithelializa-
tion begins within 10–14 days after radiation exposure in the
absence of infection (McQuestion, 2011). About a year after
radiation exposure, the skin is thin, hypovascularized, tight,
and susceptible to trauma or infection (Mendelsohn et al.,
2002). Chronic radiation skin injury includes delayed ulcers,
fibrosis, and telangiectasias that present weeks to years after
radiation exposure (Mendelsohn et al., 2002; Bridges et al.,
2009; Brown and Rzucidlo, 2011).
For many years, radiation burns (i.e., radiation skin injury)
have been treated using the same therapeutic measures
applied to thermal burns. However, the pathophysiology of
radiation burns differs from thermal burns in three major
ways (Lataillade et al., 2007; Bey et al., 2010). First, radiation
burns have a dose-dependent clinical pattern, which includes
dry desquamation at 12–20Gy, moist desquamation at
X20Gy, and necrosis at 435Gy (Mendelsohn et al., 2002;
Hymes et al., 2006; Bey et al., 2010; Wolbarst et al., 2010;
Brown and Rzucidlo, 2011). Second, radiation burns are
associated with opiate-resistant chronic pain (Lataillade et al.,
2007; Bey et al., 2010). The most complicating factor of
radiation burns is the unpredictable successive inflammatory
waves occurring weeks to years after radiation exposure
(Lataillade et al., 2007; Bey et al., 2010). These uncontrolled
inflammatory waves make it difficult to delineate the
radiation-injured tissue from noninjured tissue. Conventional
treatment for severe radiation burns combines surgical
excision of damaged tissue and reconstructive surgery, such
as full-thickness skin grafts (Lataillade et al., 2007; Bey et al.,
2010). However, successive inflammatory waves often lead
to impairment and necrosis of the newly grafted skin.
Therefore, the majority of severe radiation burns require
successive surgical excisions and reconstructions, as well as
amputation (Lataillade et al., 2007; Bey et al., 2010). Overall,
the healing of radiation burns is extensive and unpredictable.
Risk factors
Both treatment- and patient-related factors can contribute to
the risk of developing severe radiation skin injury. Technical
factors with radiotherapy that influence the degree of
radiation skin injury include radiation dose to skin, irradia-
tion site, fractionation timing, total exposure time, and angle
of radiation beam (Brown and Rzucidlo, 2011; McQuestion,
2011). The dose of radiation on the skin is directly related to
the severity of injury. Different skin areas of the body have
different sensitivities to radiation. The most sensitive skin
regions of the body are the anterior of the neck, extremities,
chest, abdomen, and face (Brown and Rzucidlo, 2011). In
addition, hair follicles on the scalp and breast tissue are both
radiosensitive compared with other regions of the body
(Brown and Rzucidlo, 2011). Patient-related factors include
preexisting conditions such as obesity, age, gender, chronic
Table 1. Acute skin changes with localized radiation
dose
Acute skin effect Dose (Gy) Onset
Early transient erythema 2 Hours
Faint erythema; epilation 6–10 7–10 Days
Definite erythema;
hyperpigmenation
12–20 2–3 Weeks
Dry desquamation 20–25 3–4 Weeks
Moist desquamation 30–40 X4 Weeks
Ulceration 440 X6 Weeks
Late skin effect
Delayed ulceration 445 Weeks after radiation
Dermal necrosis/atrophy 445 Months after radiation
Fibrosis 445 6 Months to X1 year
after radiation
Telangiectasia 445 6 Months to X1 year
after radiation
Information compiled from Mendelsohn et al., 2002; Hymes et al., 2006;
Bey et al., 2010; Wolbarst et al., 2010; and Brown and Rzucidlo, 2011.
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sun exposure, and smoking (Hymes et al., 2006; Salvo et al.,
2010; Brown and Rzucidlo, 2011; McQuestion, 2011).
Individuals with ataxia telangiectasia and hereditary nevoid
basal cell carcinoma syndrome (Gorlin Syndrome) require
dose alterations or avoidance of radiation exposure (Hymes
et al., 2006). Individuals with ataxia telangiectasia, a rare
autosomal-recessive disorder resulting in mutations in the
ATM gene, are highly susceptible to severe radiation
dermatitis. Irradiation of individuals with Gorlin Syndrome
could produce widespread cutaneous tumors. Other dis-
orders that increase the risk of radiation skin injury include
connective tissue disorders (lupus, scleroderma), chromo-
somal breakage syndromes (Fanconi’s anemia, Bloom syn-
drome), xeroderma pigmentosa, Gardner’s syndrome,
hereditary malignant melanoma, and dysplastic nevus
syndrome (Hymes et al., 2006). Older female patients have
increased risk of radiation skin injury (Hymes et al., 2006;
Salvo et al., 2010; Brown and Rzucidlo, 2011; McQuestion,
2011). A recent study in head and neck cancer patients
reported that women were at higher risk for acute and late
radiation–induced toxicities (odds ratios¼1.72 and 3.96,
respectively) compared with men (Meyer et al., 2011).
Other risk factors for severe radiation skin injury are
increased transepidermal water loss and infiltration of patho-
gens or bacteria into the skin (Elliott et al., 1990; Ledney
et al., 1991; Hill et al., 2004; Martin et al., 2010). Severe
radiation dermatitis for localized radiation has previously
been linked to Staphylococcus aureus infection (Hill et al.,
2004). Host antimicrobial defenses are severely compro-
mised by radiation and/or skin trauma combined with radi-
ation (Ledney et al., 1991). Even mice exposed to sublethal
total body radiation have increased susceptibility to bacterial
infections in wounds (Elliott et al., 1990; Ledney et al., 1991;
Konchalovsky et al., 2005; Williams and McBride, 2011).
It appears that ionizing radiation damage in the skin is
somewhat similar to atopic dermatitis. Atopic dermatitis, a
common form of eczema, affects up to 20% of children in the
United States, and is widely accepted to have a profound
effect on the stratum corneum function, and increased trans-
epidermal water loss (Murata et al., 1996; Laughter et al.,
2000; Imokawa, 2001; Pilgram et al., 2001; Choi and
Maibach, 2005; Jungersted et al., 2008). Atopic dermatitis
patients are far more susceptible to skin infections by
organisms such as Staphlococcus aureus and Herpes simplex
virus (Scott et al., 2007; Kedzierska et al., 2008; Lebre et al.,
2008; Niebuhr et al., 2008). It has been speculated that
atopic dermatitis individuals would be more susceptible to
severe radiation skin injury; however, the definitive answer
has yet to be elucidated.
Skin immune response following radiation
In addition to being the physical barrier, the skin provides a
system of immune surveillance that maintains homeostasis
and is poised to respond to environmental insults. Key cells
within the epidermal layer involved in this surveillance are
the Langerhans cells (LCs; Valladeau and Saeland, 2005).
Keratinocytes also have an important role because they are
capable of producing large amounts of cytokines, particularly
IL-1a and tumor necrosis factor-a (Takashima and Bergstres-
ser, 1996). The LCs, along with dermal dendritic cells (DCs),
are essential antigen-presenting cells and are responsible
for the uptake of antigens that may breach the skin barrier
(Kupper and Fuhlbrigge, 2004). The dermis also contains
mast cells and T cells, which are also important factors
in radiation-induced immune response (Kalesnikoff and
Galli, 2008; Stelekati et al., 2009; Muller and Meineke,
2011). Furthermore, the dermis is richly supplied with blood
vessels and lymphatic vessels, which serve as the conduits by
which migrating DCs can traffic to the draining lymph nodes
and present antigens to T cells (Kupper and Fuhlbrigge,
2004).
Ionizing radiation incites signaling between the epidermis
and dermis (Figure 1). Keratinocytes, fibroblasts, and endo-
thelial cells in the skin stimulate resident (i.e., LCs, DCs, mast
cells, T cells) and circulating immune cells (Muller and
Meineke, 2007, 2011). Numerous cytokines and chemokines
are produced in response to these activation signals, which
act on the endothelial cells of local vessels, causing the
upregulation of adhesion molecules (Muller and Meineke,
2007). Adhesion molecules that have been implicated
include intercellular adhesion molecule-1, vascular cell
adhesion molecule-1, and E-selectin (Yuan et al., 2005;
Holler et al., 2009). Transendothelial migration of immune
cells, such as neutrophils, macrophages, and leukocytes,
from circulation to irradiated skin is considered a ‘‘hallmark’’
of radiation-induced skin injury (Muller and Meineke, 2007;
Holler et al., 2009). Acute radiation skin toxicity has been
correlated with increased formation of various cytokines
and chemokines, most notably IL-1a, IL-1b, tumor necrosis
factor-a, IL-6, IL-8, CCL4, CXCL10, and CCL2 (Okunieff
et al., 2006; Xiao et al., 2006; Holler et al., 2009). Research
demonstrated that both the epidermal LCs and the dermal
DCs are depleted from the skin following local irradiation
(Cummings et al., 2009). This is time dependent and
radiation-dose dependent for both subsets of cells (Cummings
et al., 2009). An important question, which has not yet been
addressed, is whether this depletion is due to death of the
cells or by migration to the draining lymph node. The effects
of ionizing radiation on DCs are largely unknown, and in
humans they are limited to studies on populations of DCs
generated in vitro from peripheral blood mononuclear cells.
A recent study on DC populations has revealed that they do
not undergo apoptosis after as much as 30Gy and maintain
their ability to ingest particles and to migrate. However, their
antigen-presenting capabilities, as measured by their ability
to induce T-cell responses, were found to be slightly impaired
(Merrick et al., 2005). Merad et al. (2002) demonstrated
that DCs were replaced by donor cells within 2 months in
lethally irradiated C57BL/6-CD45.2þ mice that received
a bone marrow transplant from C57BL/6-CD45.1þ donor
mice. In contrast, the host LCs persisted in the recipient mice
for up to 18 months following irradiation (Merad et al., 2002).
Interestingly, in this same study, it was demonstrated that
an additional injury (UVR) resulted in rapid disappearance
of LCs and replacement by circulating LC precursors. These
studies suggest that LCs are quite radioresistant.
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Recently, Muller and Meineke (2011) demonstrated that
ionizing radiation results in degranulation of mast cells in the
dermis. Mast cell–derived histamine, serotonin, tumor necro-
sis factor-a, and tryptase significantly alter the release of
CCL8, CCL13, CXCL4, and CXCL6 by dermal fibroblasts
(Muller and Meineke, 2011). Research to date suggests that
fibroblasts are responsible for fibrosis and other late-radiation
injury (Brown and Rzucidlo, 2011; Muller and Meineke,
2007, 2011). Transforming growth factor-b (TGFb), Smad3,
vascular endothelial growth factor, and CCL11 (eotaxin) have
been identified as key mediators of radiation-induced late
injury (Okunieff et al., 2006; Xiao et al., 2006; Muller and
Meineke, 2007; Anscher, 2010). TGFb is a potent chemo-
attractant for various inflammatory cells and a stimulant for
extracellular matrix production by fibroblasts (Anscher, 2010;
Lee et al., 2010). TGFb initiates a fibrotic response through its
receptor Smad3 on fibroblasts (Anscher, 2010; Lee et al.,
2010). Reduction in radiation-induced fibrosis in Smad3
knockout mice has demonstrated its link to late-radiation skin
injury (Ashcroft et al., 1999; Flanders et al., 2002, 2003; Lee
et al., 2010).
Oxidative stress is generated at the time of radiation
exposure, as well as days after irradiation, because of the
propagation of free radicals (Benderitter et al., 2007).
Radiation skin injury also involves imbalances in antioxidant
status and redox control of wound healing (Benderitter
et al., 2007; Holler et al., 2009; Muller and Meineke, 2007,
2011; Williams and McBride, 2011). The immediate damage
caused by ionizing radiation is a result of robust, but
transient, production of reactive oxygen species (Williams
and McBride, 2011). However, inflammatory cell recruitment
and cytokine generation also lead to chronic generation of
reactive oxygen species. Specific genes that have been
implicated in oxidative stress following radiation exposures
include superoxide dismutases, glutathione peroxidases,
thioredoxins, heme-oxygenases, and heat-shock protein-27
(Benderitter et al., 2007; Williams and McBride, 2011).
Superoxide dismutase-1, glutathione peroxidase-1, thio-
redoxins-1, -2, and heat-shock protein-27 were upregulated
in healing skin after irradiation. However, these genes were
downregulated, whereas heme-oxygenases-1 and -2 were
upregulated in nonhealing skin after irradiation (Benderitter
et al., 2007). Benderitter et al. (2007) further implicated
a T helper type-2-mediated immune response for nonresolu-
tion of inflammatory response and delayed wound healing
following irradiation. Catalase has also been identified as
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Figure 1. Schematic identifying the key cells and mediators involved in radiation skin injury. Ionizing radiation incites signaling between the epidermis
and dermis through resident skin cells. In the epidermis, immediate damage to the basal keratinocytes and burst of free radicals result in the increased formation
of various cytokines and chemokines, most notably IL-1a, IL-1b, TNFa, IL-6, IL-8, CCL4, CXCL10, and CCL2. Keratinocytes, along with fibroblasts and
endothelial cells in the dermis, stimulate resident skin cells and recruit circulating immune cells, such as neutrophils and macrophages. In addition, Langerhans
cells in the epidermis and dendritic cells in the dermis migrate to lymph nodes for antigen presentation and immune cell stimulation. Degranulation of
mast cells releases histamine, serotonin, TNFa, and tryptase. Fibroblast stimulation is involved in acute skin injury, late skin injury, and healing of radiation
skin injury. Oxidative stress is generated at the time of radiation exposure, as well as days after irradiation, because of propagation of free radicals and
inflammatory cell recruitment, creating an antioxidant imbalance. bFGF, basic fibroblast growth factor; EGF, epidermal growth factor; ICAM-1, intercellular
adhesion molecule-1; KGF, keratinocyte growth factor; RNS, reactive nitrogen species; ROS, reactive oxygen species; TNFa, tumor necrosis factor-a;
TSLP, thymic stromal lymphopoietin; VCAM-1, vascular cell adhesion molecule-1; VEGF, vascular endothelial growth factor.
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a potential mitigator for radiation skin injury because
of its ability to reduce tumor necrosis factor-a-induced
production of cytokines and reactive oxygen species
(Doctrow et al., 1997; Young et al., 2008; Rosenthal et al.,
2011).
AREAS NEEDING INVESTIGATION: WEAKNESSES IN
MEASUREMENT AND TREATMENT
Measuring severity of radiation skin injury
A gold standard for clinically rating the severity of radiation
skin injury does not exist (Table 2). The most commonly used
scoring systems are the National Institutes of Health Common
Toxicity Criteria-Adverse Event (CTCAE) and the Radiation
Therapy Oncology Group toxicity scoring system (Salvo
et al., 2010). However, other scoring scales, such as the
Oncology Nursing Society, Douglas & Fowler, and Radiation
Dermatitis Severity scales, have been developed to more
accurately represent the varying levels of the actual skin
reaction. In contrast to the CTCAE and Radiation Therapy
Oncology Group scoring systems, the newer scales have
smaller defined increments to represent subtle, yet critical,
changes in the skin. The CTCAE and Radiation Therapy
Oncology Group scales range from 0 to 4 with increments
of 1, whereas the Oncology Nursing Society, Douglas &
Fowler, and Radiation Dermatitis Severity scales range from
0 to 4 or 1 to 5 with increments of 0.5. Table 2 shows the
various scoring systems used to measure acute radiation-
induced skin reactions. Radiation-induced late effects in the
skin are primarily rated by the Radiation Therapy Oncology
Group/European Organization for Research and Treatment of
Cancer or Late Effects Normal Tissue Task Force/Subjective,
Objective, Management, and Analytic classifications, which
range from Grade 1 to 4 (Hoeller et al., 2003). Both scales
measure late skin changes and subcutaneous tissue changes,
but the Late Effects Normal Tissue Task Force/Subjective,
Objective, Management, and Analytic scale also incorporates
pain intensity.
Over the past few years, patient-reported outcomes have
become common instruments to aid in accurate assessment
of various symptoms (Neben-Wittich et al., 2010). Recently,
Neben-Wittich et al. (2010) reported that the Skindex-16 and
Skin Toxicity Assessment Tool, two patient-report outcome
instruments, did not correlate with the CTCAE scoring system.
Both patient-report outcome instruments provided a more
complete measure of toxicity compared with the CTCAE
scores. The importance of patient-report outcome instruments
in radiation skin toxicity is further supported by a compara-
tive study conducted in 2007 (Ryan et al., 2007). Ryan
et al. (2007) demonstrated a disconnect between clinically
reported and patient-reported radiation-induced skin reac-
tion. The study showed that African Americans reported
more severe posttreatment skin reactions compared with
Caucasians after receiving radiation therapy. Both these
studies (Ryan et al., 2007; Neben-Wittich et al., 2010)
demonstrate that patient-reported information is critical for
effective symptom management. Overall, further research is
required for the development of a standard and accurate
scoring system for radiation skin injury.
Table 2. Comparison of acute radiation skin injury
scoring systems
Score Observation
Radiation Therapy Oncology Group
0 No change over baseline
1 Erythema; dry desquamation; epilation
2 Bright erythema; moist desquamation; edema
3 Confluent moist desquamation; pitting edema
4 Ulceration, hemorrhage, necrosis
NIH CTCAE
0 None
1 Faint erythema or dry desquamation
2 Moderate to brisk erythema
3 Confluent moist desquamation
4 Skin necrosis or ulceration
Oncology Nursing Society
0 No change
1.0 Faint or dull erythema
1.5 Bright erythema
2.0 Dry desquamation with or without erythema
2.5 Small to moderate amount of moist desquamation
3.0 Confluent moist desquamation
3.5 Ulceration, hemorrhage, or necrosis
Douglas & Fowler
0 Normal
0.25 50/50, Doubtful if any difference from normal
0.5 Very slight reddening
0.75 Definite but slight reddening
1 Severe reddening
1.25 Severe reddening with white scale; ‘‘papery’’ appearance
of skin
1.5 Moist breakdown in one very small area with scaly or crusty
appearance
1.75 Moist desquamation in more than one small area
2 Moist desquamation in 25% of irradiated area
2.25 Moist desquamtion in 33% of irradiated area
2.5 Moist desquamation in 50% of irradiated area
2.75 Moist desquamation in 66% of irradiated area
3 Moist desquamation in most of irradiated area
3.25 Moist desquamation in most of irradiated area with slight moist
exudate
3.5 Moist desquamation in most of irradiated area with moist
exudates; necrosis
Table 2 continued on the following page
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Evidence-based management of radiation skin injury
Over the years, ‘‘washing with mild soap’’ has been the only
intervention recommended for radiation-induced skin reac-
tions (Bolderston et al., 2006; McQuestion, 2006). In 2010, a
systematic review revealed a lack of evidence to support
‘‘washing with mild soap’’ as an intervention for radiation-
induced skin reactions (Salvo et al., 2010). In this study (Salvo
et al., 2010), although topical corticosteroid and nonsteroidal
creams appeared to reduce the severity of skin reactions, there
was no clear indication of a preferred topical agent. Amifostine
and oral enzymes emerged as somewhat effective preventative
agents, whereas pentoxifylline reduced late, but not acute,
effects of radiation on the skin (Benderitter et al., 2010; Muller
and Meineke, 2010; Salvo et al., 2010). Long treatment (X3
years) of pentoxifylline and tocopherol (i.e., vitamin E)
significantly reduced radiation-induced fibrosis. Unfortunately,
cessation of pentoxifylline–tocopherol treatment before 3 years
resulted in a ‘‘rebound effect’’ and more severe radiation-
induced fibrosis (Delanian et al., 2005). In addition, intensity-
modulated radiation therapy was acknowledged as a
technological intervention that has significantly reduced skin
reactions from radiation (Pignol et al., 2008; Muller and
Meineke, 2010; Salvo et al., 2010). In 2011, McQuestion
(2011) published evidence-based guidelines for skin care
management in radiation therapy, which recommended the
following: (1) washing with lukewarm water and mild soap, (2)
using unscented, lanolin-free, water-based moisturizing cream,
and (3) intensity-modulated radiation therapy. Overall, an effec-
tive intervention for radiation-induced skin reactions remains to
be elucidated (Salvo et al., 2010; McQuestion, 2011).
National Cancer Institute and the National Institute of
Allergy and Infectious Disease both have interest in the
development of effective radiation mitigators and protectors
(Ryan et al., 2011a). Because of the unpredictability and
barriers to medical treatment following a radiological or
nuclear event, an effective remediation strategy must be a
radiation mitigator (Williams and McBride, 2011; Ryan et al.,
2011a). However, for cancer radiotherapy, elucidation of the
differences in the mechanisms involved in the response of
skin and other normal tissues to radiation in comparison with
tumors is a critical component in this development (Ryan
et al., 2011a). Most importantly, interventions that ameliorate
radiation-induced toxicities in one scenario of radiation
exposure may also work in other scenarios of exposure
(i.e., ‘‘dirty bomb’’ vs. radiotherapy).
Targeted gene therapy has emerged as a promising
radiation mitigator and protector. Preclinical studies have
identified the following potential targets: TGFb1 pathway
inhibitor (Anscher, 2010; Lee et al., 2010), synthetic super-
oxide dismutase/catalase mimetics (Greenberger, 2008;
Rosenthal et al., 2011), recombinant IL-12 (Cummings
et al., 2009), toll-like receptor-5 agonist (Burdelya et al.,
2008; Gudkov and Komarova, 2010), and inhibitors of
cyclin-dependent kinases (Gudkov and Komarova, 2010).
Furthermore, pravastatin reduced radiation skin injury by
maintaining endothelial cell function after radiation exposure
by increasing endothelial nitric oxide synthase (Holler et al.,
2009). Curcumin, a component of turmeric, has also
demonstrated the ability to reduce radiation skin toxicity
through its potent antioxidant and anti-inflammatory acti-
vities (Okunieff et al., 2006; Ryan et al., 2011b). Recently,
Atiba et al. (2011) observed that acceleration of radiation
delayed wound healing in mice upon stimulation of TGFb-1
and basic fibroblast growth factor, suggesting that the growth
factor treatment may mitigate radiation skin injury. Although
these agents still require formal and extensive clinical testing,
the targeted approach appears specific and propitious.
Recently, stem cell therapy combined with surgical
excision has demonstrated success in improving wound
repair of severe radiation burns. As previously discussed,
surgical excision and grafting of radiation burns is compli-
cated because of the ill-defined margins of radiation damage.
Lataillade et al. (2007) used dosimetry-guided excision and
mesenchymal stem cell injections to promote healing of a
severe radiation burn on a man’s buttocks from Iridium-192.
After failure of the initial surgical excision and skin graft, a
secondary excision was performed followed by mesenchymal
stem cell injections around the lesion at the cutaneous and
muscular levels, as well as in the bed of the lesion under
the skin graft. No recurrence of radiation burn was observed
5.5 months after radiation (Lataillade et al., 2007). Similarly,
Bey et al. (2010) used five local mesenchymal stem cell
administrations combined with surgical excision and auto-
graft on the arm of a man exposed to Iridium-192. Although
the arm had functional and cosmetic limitations, there was
no recurrence of the radiation burn. Ebrahimian et al.
(2009) demonstrated that adipose tissue–derived stem cells
also promote wound healing in irradiated skin of mice.
Control of inflammatory waves, improved wound healing,
and stabilization of skin barrier are imperative to minimizing
Table 2. Continued
Score Observation
Radiation dermatitis severity scale
0.0 Normal or none
0.5 Patchy faint/slight follicular eyrthema; faint hyperpigmentation
1.0 Faint and diffuse erythema; diffuse hyperpigmentation; mild
epilation
1.5 Definite erythema; extreme darkening/hyperpigmentation
2.0 Definite erythema/hyperpigmentation with fine dry
desquamation; mild edema
2.5 Definite erythema/hyperpigmentation with branny/scaly
desquamation
3.0 Deep red erythema with diffuse dry desquamation; peeling in
sheets
3.5 Violaceous erythema with early moist desquamation; peeling in
sheets; patchy crusting
4.0 Violaceous erythema with diffuse moist desquamation; patchy
crusting; ulceration; necrosis
Abbreviation: NIH/CTCAE, National Institutes of Health Common
Toxicity Criteria—Adverse Event.
Data compiled from Pommier et al., 2004; Elliott et al., 2006; Okunieff
et al., 2006; Xiao et al., 2006; Holler et al., 2009; Jensen et al., 2011; and
Ryan et al., 2011b.
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radiation-induced skin injury from localized or total body
radiation exposure.
FUTURE CHALLENGES: CUTANEOUS RADIATION
SYNDROME AND COMBINED INJURY
Recent events in Japan, the United Kingdom involving
radioactive Polonium-210, as well as the nuclear weapons
testing in North Korea, suggest increased potential for and
reality of a nuclear and/or radiological event. It is recognized
that any skin injury in the setting of radiation poisoning greatly
increases the risk of death. Skin injury due to radiation
exposure is a major component of the multi-organ toxicity,
which could occur because of an industrial or terrorist-related
incident (Jungersted et al., 2008). A second injury, such as a
burn, or wound after nonlethal or sublethal radiation exposure
significantly increases mortality fromB12 to 75% (Jiao et al.,
2009; Homeland Security Council, 2009). The combined
injury effect of trauma or burns with total body radiation
injury at Hiroshima lowered the LD95 and LD50 by
approximately 2Gy (Flynn and Goans, 2006). These data
confirm that a lower dose of radiation is required when
combined with skin trauma or burns to cause death in 95
(LD95) or 50% (LD50) of individuals. Prolonged contact with
fallout on the skin can result in serious skin damage plus
increased total body dose (Flynn and Goans, 2006; Bridges
et al., 2009). A 10 kiloton nuclear device has the potential to
inflict second-degree burns on exposed skin up to 1.4 miles
from ground zero, whereas a 1 megaton device could inflict
second-degree burns within 15 miles from ground zero
(DiCarlo et al., 2011). In the Chernobyl Nuclear Power Plant
accident, skin involvement ranged from 4 to 50% of the total
body surface from g-ray (Cs-137) and b-particle (Sr-90)
emissions (Gottlober et al., 2001), permitting detailed obser-
vation of cutaneous radiation syndrome. Early radiation
changes in skin, such as erythema and blistering, were
observed within a year after the accident. Late radiation
changes in the skin were observed 14 years after the accident
and included epidermal atrophy, telangiectasias, keratoses,
pigment changes, fibrosis, and ulcers (Gottlober et al., 2001).
More generally, acute radiation effects in skin occur between
12hours and 5 weeks, and include erythema, pigmentation
changes, dry desquamation, and moist desquamation.
Chronic radiation effects in the skin can take weeks to years
to appear, and include fibrosis, necrosis, ulceration, and
vascular damage (Williams, 1988). Vascular damage influ-
ences levels of nutrients, oxygen available to skin tissue, as
well as epithelial cell viability. The resultant fibrosis is a
chronic, slowly cumulative effect and represents a hyponutri-
tional state of the dermis (Hall and Giaccia, 2006). Although
the skin reactions appear similar between cutaneous radiation
syndrome and localized irradiation, cutaneous radiation
syndrome also involves multi-organ exposure from total body
radiation (Williams and McBride, 2011). Therefore, the
complications from combined or secondary injury to the skin
following sublethal total body radiation exposure are a direct
result of radiation-induced multi-organ dysfunction.
Research of cutaneous radiation syndrome from total body
irradiation is limited because prospective human studies are
unethical and radiological/nuclear events are unpredictable.
Much of our understanding of cutaneous radiation syndrome
comes from our comprehension of localized skin irradiation.
However, the National Institutes of Allergy and Infectious
Disease has established a network of Centers for Medical
Countermeasures against Radiation, a collaborative network
of academic institutions, whose primary goal is to identify,
develop, and deploy medical countermeasures for radiation
toxicity after an unfortunate event (Williams and McBride,
2011). To plan effective remediation strategies, knowledge
about mechanisms responsible for acute and chronic radia-
tion effects in skin, from localized and total body irradiation,
is needed.
SUMMARY
Over the past 10 years, the field of radiation skin injury
has made substantial progress. This review summarizes the
strengths and weaknesses in published research. An expan-
sion in the knowledge on the mechanistic effects of radiation
in skin, as well as other normal tissues, has enabled
innovative growth. Unfortunately, no gold standard exists
for the measurement or management of radiation skin injury.
Development of agents to prevent or mitigate radiation skin
injury will benefit the general population, as well as patients
receiving cancer treatment.
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